^{†}There was also an increase from baseline in predose FEV_{1} at Week 24 for BEVESPI AEROSPHERE vs glycopyrrolate 18 mcg (59 mL) and formoterol fumarate 9.6 mcg (64 mL) (both *P*<0.0001).^{1,2} Statistically significant improvement in morning predose FEV_{1} was also demonstrated in Trial 2.^{1,2} In Trial 2, change in morning predose FEV_{1} at Week 24 with BEVESPI AEROSPHERE (n=433) was 103 mL vs placebo (n=170, *P*<0.0001), 54 mL vs glycopyrrolate 18 mcg (n=367, *P*=0.0003), and 56 mL vs formoterol fumarate 9.6 mcg (n=350, *P*=0.0002).^{1,2}

^{‡}In Trial 2, the mean increase in FEV_{1} at 5 minutes after the first dose vs placebo (n=179) was 186 mL for BEVESPI AEROSPHERE (n=429), 46 mL for glycopyrrolate 18 mcg (n=371), and 169 mL for formoterol fumarate 9.6 mcg (n=375). The mean increase in FEV_{1} at 120 minutes after the first dose vs placebo (n=221) was 267 mL for BEVESPI AEROSPHERE (n=506), 127 mL for glycopyrrolate 18 mcg (n=435), and 227 mL for formoterol fumarate 9.6 mcg (n=433) (*P*<0.0001 for all).^{1,2}

**References:
**
**1.
** BEVESPI AEROSPHERE [Package Insert]. Wilmington, DE: AstraZeneca; 2016.
**2.
** Martinez FJ et al. *Chest*. 2017;151(2):340-357.